CF102: Interim Phase I/II data

Interim data from an ongoing, open-label, dose-escalation, Israeli Phase I/II trial in 18 patients with advanced HCC showed that twice-daily 1, 5 and 25 mg doses of oral CF102 demonstrated a favorable...